Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like V*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187006410 ATIVAN® Tablets 1mg 1,000s 02/06/2020 2554.56 34890.72 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187006301 ATIVAN® Tablets .5mg 100s 02/06/2020 195.26 2666.86 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187006401 ATIVAN® Tablets 1mg 100s 02/06/2020 260.83 3562.53 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187006501 ATIVAN® Tablets 2mg 100s 02/06/2020 415.69 5677.56 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187301220 MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle 01/09/2020 74.41 1314.63 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187301030 MESTINON 60mg TABLETS 100s (pyridostigmine bromide) 01/09/2020 91.61 1618.51 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187301330 MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT 01/09/2020 52.13 920.95 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 66490069110 MYSOLINE 250 mg TABLETS, 100s (primidone) 02/06/2020 374.17 5110.50 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 66490069010 MYSOLINE 50 mg TABLETS, 100s (primidone) 02/06/2020 108.73 1485.06 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187305050 ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75% 50g Pump 01/09/2020 33.55 592.71 08/05/2029 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187442010 PEPCID® (Famotidine) Tablets, 20mg, 100 01/09/2020 64.29 1135.80 None Non-innovator Multiple Source Drug None 1 None 1 None 1 02/10/2015 Marathon Pharmaceuticals, LLC 286000000 None Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. 309.13 309.13 2012 222.22 None The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187442030 PEPCID® (Famotidine) Tablets, 20mg, 30 01/09/2020 19.29 340.75 None Non-innovator Multiple Source Drug None 1 None 1 None 1 02/10/2015 Marathon Pharmaceuticals, LLC 286000000 None Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. 92.74 92.74 2012 66.67 None The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187444010 PEPCID® (Famotidine) Tablets, 40mg, 100 01/09/2020 124.26 2195.32 None Non-innovator Multiple Source Drug None 1 None 1 None 1 02/10/2015 Marathon Pharmaceuticals, LLC 286000000 None Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. 597.50 597.50 2014 597.50 None The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187444030 PEPCID® (Famotidine) Tablets, 40mg, 30 01/09/2020 37.28 658.56 None Non-innovator Multiple Source Drug None 1 None 1 None 1 02/10/2015 Marathon Pharmaceuticals, LLC 286000000 None Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. 179.24 179.24 2014 179.24 None The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187149825 TIMOPTIC? in OCUDOSE? (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL Vial 01/09/2020 25.10 443.37 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 11/6/2015 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2020 00187149605 TIMOPTIC? in OCUDOSE? (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL Vial 01/09/2020 28.62 505.59 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 8/9/2015 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed.
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2020 43068010102 Fanapt 1 mg tablets; bottles of 60 01/01/2020 94.17 1271.27 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2020 43068010102 Fanapt 1 mg tablets; bottles of 60 09/14/2020 114.41 1385.68 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2020 43068011002 Fanapt 10 mg tablets; bottles of 60 01/01/2020 185.56 2505.01 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2020 43068011002 Fanapt 10 mg tablets; bottles of 60 09/14/2020 225.45 2730.46 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2020 43068011202 Fanapt 12 mg tablets; bottles of 60 01/01/2020 185.56 2505.01 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2020 43068011202 Fanapt 12 mg tablets; bottles of 60 09/14/2020 225.45 2730.46 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2020 43068010202 Fanapt 2 mg tablets; bottles of 60 01/01/2020 94.17 1271.27 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2020 43068010202 Fanapt 2 mg tablets; bottles of 60 09/14/2020 114.41 1385.68 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2020 43068010402 Fanapt 4 mg tablets; bottles of 60 01/01/2020 94.17 1271.27 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2020 43068010402 Fanapt 4 mg tablets; bottles of 60 09/14/2020 114.41 1385.68 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2020 43068010602 Fanapt 6 mg tablets; bottles of 60 01/01/2020 115.87 1564.21 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2020 43068010602 Fanapt 6 mg tablets; bottles of 60 09/14/2020 140.78 1704.99 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2020 43068010802 Fanapt 8 mg tablets; bottles of 60 01/01/2020 115.87 1564.21 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2020 43068010802 Fanapt 8 mg tablets; bottles of 60 09/14/2020 140.78 1704.99 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2020 43068011304 Fanapt 8 tablet titration pack (1mg, 2mg, 4mg, 6mg) 01/01/2020 12.57 169.52 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2020 43068011304 Fanapt 8 tablet titration pack (1mg, 2mg, 4mg, 6mg) 09/14/2020 15.26 184.78 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2020 43068022001 Hetlioz; 20 mg capsules; bottles of 30 01/01/2020 942.08 16643.43 07/27/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 12/31/2020 43068022001 Hetlioz; 20 mg capsules; bottles of 30 10/01/2020 1997.21 18640.64 08/29/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025007130 CONZIP (tramadol hydrochloride), CAPSULE EXTENDED RELEASE, 100 mg, 30 ct 01/01/2020 25.32 341.82 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Drug was not aquired within the last 5 years
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025007230 CONZIP (tramadol hydrochloride), CAPSULE EXTENDED RELEASE, 200 mg, 30 ct 01/01/2020 33.18 447.96 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Drug was not aquired within the last 5 years
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025007330 CONZIP (tramadol hydrochloride), CAPSULE EXTENDED RELEASE, 300 mg, 30 ct 01/01/2020 45.90 619.62 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Drug was not aquired within the last 5 years
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025005230 CORVITE 150, TABLET, MULTI, 30 ct 01/01/2020 9.58 129.32 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025006030 CORVITE FE, TABLET, MULTI, 30 ct 01/01/2020 12.60 170.11 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025006530 DIVIGEL (estradiol gel) GEL, 0.25 mg, 30 ct 01/01/2020 9.97 142.89 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Drug was not aquired within the last 5 years
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025006630 DIVIGEL (estradiol gel) GEL, 0.50 mg, 30 ct 01/01/2020 9.97 142.89 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Drug was not aquired within the last 5 years
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025008330 DIVIGEL (estradiol gel) GEL, 0.75 mg, 30 ct 01/01/2020 9.97 142.89 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Drug was not aquired within the last 5 years
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025006730 DIVIGEL (estradiol gel) GEL, 1.0 mg, 30 ct 01/01/2020 9.97 142.89 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Drug was not aquired within the last 5 years
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025004610 LORZONE (chlorzoxazone USP) TABLET, 375 mg, 30 ct 01/01/2020 81.87 908.86 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Drug was not aquired within the last 5 years
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025004710 LORZONE (chlorzoxazone USP) TABLET, 750 mg, 30 ct 01/01/2020 91.55 1016.26 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Drug was not aquired within the last 5 years
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025004960 OB COMPLETE DHA, SOFTGEL CAPSULE, MULTI, 60 ct 01/01/2020 13.07 176.50 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025004430 OB COMPLETE ONE, CAPSULE, MULTI, 30 ct 01/01/2020 13.31 179.67 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025005930 OB COMPLETE PETITE, SOFTGEL CAPSULE, MULTI, 30 ct 01/01/2020 12.90 174.18 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025004330 OB COMPLETE PREMIER, TABLET, MULTI, 30 ct 01/01/2020 9.33 125.92 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 03/31/2020 68025001010 OB COMPLETE PRENATAL, CAPLET, MULTI, 100ct 01/01/2020 16.63 224.51 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000066 ViiV Healthcare 03/31/2020 49702022613 TIVICAY TAB 10MG - 30 tablets per bottle 01/01/2020 17.20 365.30 12/08/2029 Single Source Drug None 1 None 1 The price increase listed are not related to any identified or claimed change or improvement. None None None None None None None None None None None Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066 ViiV Healthcare 03/31/2020 49702022713 TIVICAY TAB 25MG - 30 tablets per bottle 01/01/2020 42.99 913.24 12/08/2029 Single Source Drug None 1 None 1 The price increase listed are not related to any identified or claimed change or improvement. None None None None None None None None None None None Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066 ViiV Healthcare 03/31/2020 49702022813 TIVICAY TAB 50MG - 30 tablets per bottle 01/01/2020 85.98 1826.47 12/08/2029 Single Source Drug None 1 None 1 The price increase listed are not related to any identified or claimed change or improvement. None None None None None None None None None None None Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.